Adaptive Biotechnologies (ADPT) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$26.49
+1.5% on the day
+69.3% over 12 months
52-week range $12.41 – $29.84
Share price and insider trades
ADPT closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$125M
Insiders buying0
Insiders selling11
Adaptive Biotechnologies insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 11 sold $125M of ADPT stock on the open market.
Get emailed when insiders cluster-buy stocks like ADPT
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
ADPT insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $2.9M | 14 |
| Q3 2026 | — | 0 | $46.3M | 25 |
| Q2 2026 | — | 0 | $15.0M | 36 |
| Q1 2026 | — | 0 | $39.6M | 51 |
| Q4 2025 | — | 0 | $21.0M | 17 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day0.9×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Adaptive Biotechnologies Corp insiders reported open-market purchases totaling $0, while 11 insiders reported sales totaling $125M. 121 of 143 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
ADPT earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Jul 29, 2026 | +7.1% | Sold $27.2M | +7.4%S&P +0.1% | +4.2% |
| May 5, 2026 | +0.2% | Sold $6.9M | -0.5%S&P +2.2% | +17.1% |
| Feb 5, 2026 | -3.2% | Sold $4.8M | -8.8%S&P +0.6% | -5.8% |
| Jan 12, 2026 | -5.5% | Sold $4.1M | +14.7%S&P -0.0% | -14.0% |
| Nov 5, 2025 | -5.1% | None | -8.0%S&P -0.7% | -5.2% |
| Aug 5, 2025 | +5.0% | None | +7.1%S&P +0.3% | +9.9% |
| May 1, 2025 | -4.9% | None | +33.7%S&P +2.2% | -3.3% |
| Feb 11, 2025 | -3.9% | None | -1.7%S&P -0.2% | -3.6% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 8SEC | Julie RubinsteinCOO, President | Sell Plan | 11,881377,802 held (−3%) | $26.40 | $314K | +0.3% | — |
| Oct 8SEC | Julie RubinsteinCOO, President | Sell Plan | 11,881377,802 held (−3%) | $25.66 | $305K | +3.2% | — |
| Oct 8SEC | Julie RubinsteinCOO, President | Sell Plan | 9,381380,302 held (−2%) | $27.36 | $257K | -3.2% | — |
| Oct 8SEC | Susan BobulskyChief Commercial Officer, Mrd | Sell Plan | 6,444389,350 held (−2%) | $30.00 | $193K | -11.7% | — |
| Oct 8SEC | Julie RubinsteinCOO, President | Sell Plan | 1,100379,202 held (−0%) | $28.21 | $31K | -6.1% | — |
| Oct 8SEC | Julie RubinsteinCOO, President | Sell Plan | 901378,301 held (−0%) | $29.71 | $27K | -10.8% | — |
| Oct 8SEC | Julie RubinsteinCOO, President | Sell Plan | 499377,802 held (−0%) | $30.53 | $15K | -13.2% | — |
| Oct 5SEC | Francis LoChief People Officer | Sell Plan | 18,698220,867 held (−8%) | $28.61 | $535K | -7.4% | — |
| Oct 5SEC | Julie RubinsteinCOO, President | Sell Plan | 11,881377,802 held (−3%) | $28.13 | $334K | -5.8% | — |
| Oct 5SEC | Francis LoChief People Officer | Sell Plan | 8,094239,565 held (−3%) | $27.52 | $223K | -3.7% | — |
| Oct 5SEC | Julie RubinsteinCOO, President | Sell Plan | 6,699382,984 held (−2%) | $28.82 | $193K | -8.1% | — |
| Oct 5SEC | Julie RubinsteinCOO, President | Sell Plan | 6,081383,602 held (−2%) | $27.57 | $168K | -3.9% | — |
| Oct 5SEC | Julie RubinsteinCOO, President | Sell Plan | 5,800377,802 held (−2%) | $28.56 | $166K | -7.2% | — |
| Oct 5SEC | Julie RubinsteinCOO, President | Sell Plan | 5,182377,802 held (−1%) | $29.67 | $154K | -10.7% | — |
| Sep 18SEC | Francis LoChief People Officer | Sell Plan | 107,537228,736 held (−32%) | $28.02 | $3.0M | -5.5% | — |
| Sep 18SEC | Francis LoChief People Officer | Sell Plan | 7,869220,867 held (−3%) | $28.57 | $225K | -7.3% | — |
| Sep 17SEC | Susan BobulskyChief Commercial Officer, Mrd | Sell Plan | 1,195395,794 held (−0%) | $27.00 | $32K | -1.9% | — |
| Aug 28SEC | Katey Einterz OwenDirector | Sell | 9,61578,639 held (−11%) | $26.00 | $250K | +1.9% | — |
| Aug 20SEC | Robert HershbergDirector | Sell | 15,66446,683 held (−25%) | $24.41 | $382K | +8.5% | — |
| Aug 20SEC | Robert HershbergDirector | Sell | 15,00062,347 held (−19%) | $24.39 | $366K | +8.6% | — |
| Aug 19SEC | Chad M RobinsCEO, Chair | Sell | 318,7992,183,043 held (−13%) | $25.08 | $8.0M | +5.6% | — |
| Aug 19SEC | Chad M RobinsCEO, Chair | Sell | 278,4722,180,722 held (−11%) | $24.48 | $6.8M | +8.2% | — |
| Aug 19SEC | Peter M NeupertDirector | Sell | 69,690130,625 held (−35%) | $25.16 | $1.8M | +5.3% | — |
| Aug 19SEC | Peter M NeupertDirector | Sell | 40,000200,315 held (−17%) | $25.10 | $1.0M | +5.5% | — |
| Aug 19SEC | Peter M NeupertDirector | Sell | 15,000240,315 held (−6%) | $25.23 | $378K | +5.0% | — |
| Aug 19SEC | Chad M RobinsCEO, Chair | Sell | 2,5252,180,518 held (−0%) | $25.57 | $65K | +3.6% | — |
| Aug 19SEC | Chad M RobinsCEO, Chair | Sell | 2042,180,518 held (−0%) | $25.14 | $5K | +5.4% | — |
| Aug 12SEC | Susan BobulskyChief Commercial Officer, Mrd | Sell Plan | 3,000396,989 held (−1%) | $25.00 | $75K | +6.0% | — |
| Aug 3SEC | Susan BobulskyChief Commercial Officer, Mrd | Sell Plan | 1,299399,989 held (−0%) | $24.00 | $31K | +10.4% | — |
| Jul 23SEC | Harlan S RobinsChief Scientific Officer | Sell Plan | 278,6981,025,760 held (−21%) | $21.72 | $6.1M | +22.0% | — |
| Jul 23SEC | Harlan S RobinsChief Scientific Officer | Sell Plan | 213,702812,058 held (−21%) | $22.12 | $4.7M | +19.8% | — |
| Jul 20SEC | Susan BobulskyChief Commercial Officer, Mrd | Sell Plan | 5,000401,288 held (−1%) | $23.00 | $115K | +15.2% | — |
| Jul 17SEC | Francis LoChief People Officer | Sell Plan | 105,762230,713 held (−31%) | $22.59 | $2.4M | +17.3% | — |
| Jul 7SEC | Harlan S RobinsChief Scientific Officer | Sell Plan | 239,3511,166,547 held (−17%) | $21.74 | $5.2M | +21.8% | — |
| Jul 7SEC | Harlan S RobinsChief Scientific Officer | Sell Plan | 146,8891,019,658 held (−13%) | $22.45 | $3.3M | +18.0% | — |
| Jul 6SEC | Francis LoChief People Officer | Sell Plan | 44,838230,713 held (−16%) | $22.59 | $1.0M | +17.3% | — |
| Jul 6SEC | Francis LoChief People Officer | Sell Plan | 42,261237,688 held (−15%) | $22.50 | $951K | +17.7% | — |
| Jul 6SEC | Francis LoChief People Officer | Sell Plan | 8,743279,949 held (−3%) | $22.18 | $194K | +19.4% | — |
| Jul 6SEC | Susan BobulskyChief Commercial Officer, Mrd | Sell Plan | 487406,288 held (−0%) | $22.00 | $11K | +20.4% | — |
| Jun 30SEC | Sharon BenzenoChief Commercial Ofc Imm Med | Sell Plan | 154,768221,278 held (−41%) | $21.14 | $3.3M | +25.3% | — |
| Jun 30SEC | Sharon BenzenoChief Commercial Ofc Imm Med | Sell Plan | 11,034272,751 held (−4%) | $21.00 | $232K | +26.1% | — |
| Jun 29SEC | Michelle Renee GriffinDirector | Sell Plan | 52,08415,625 held (−77%) | $20.18 | $1.1M | +31.3% | — |
| Jun 29SEC | Susan BobulskyChief Commercial Officer, Mrd | Sell Plan | 5,000406,775 held (−1%) | $20.50 | $102K | +29.2% | — |
| Jun 17SEC | Harlan S RobinsChief Scientific Officer | Sell Plan | 100,0001,412,058 held (−7%) | $17.37 | $1.7M | +52.5% | — |
| Jun 17SEC | Harlan S RobinsChief Scientific Officer | Sell Plan | 6,1601,405,898 held (−0%) | $18.01 | $111K | +47.1% | — |
| Jun 15SEC | Susan BobulskyChief Commercial Officer, Mrd | Sell Plan | 5,000411,775 held (−1%) | $19.00 | $95K | +39.4% | — |
| Jun 8SEC | Francis LoChief People Officer | Sell Plan | 39,741250,934 held (−14%) | $17.49 | $695K | +51.5% | — |
| Jun 8SEC | Susan BobulskyChief Commercial Officer, Mrd | Sell Plan | 11,000416,775 held (−3%) | $18.00 | $198K | +47.2% | — |
| May 20SEC | Kyle PiskelCFO | Sell | 3,115256,725 held (−1%) | $13.04 | $41K | +103.1% | — |
| Apr 29SEC | Julie RubinsteinCOO, President | Sell Plan | 19,037377,802 held (−5%) | $14.23 | $271K | +86.2% | — |
| Apr 24SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060390,808 held (−5%) | $14.13 | $269K | +87.5% | — |
| Apr 24SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060382,132 held (−5%) | $14.02 | $267K | +88.9% | — |
| Apr 24SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060386,470 held (−5%) | $13.74 | $262K | +92.8% | — |
| Apr 21SEC | Julie RubinsteinCOO, President | Sell Plan | 30,941395,146 held (−7%) | $14.66 | $454K | +80.7% | — |
| Apr 21SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060403,822 held (−5%) | $14.57 | $278K | +81.8% | — |
| Apr 21SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060399,484 held (−5%) | $14.55 | $277K | +82.1% | — |
| Apr 16SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060412,498 held (−4%) | $14.61 | $278K | +81.3% | — |
| Apr 16SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060416,836 held (−4%) | $14.56 | $278K | +81.9% | — |
| Apr 16SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060408,160 held (−4%) | $14.18 | $270K | +86.8% | — |
| Apr 13SEC | Julie RubinsteinCOO, President | Sell Plan | 18,660425,912 held (−4%) | $12.75 | $238K | +107.8% | — |
| Apr 13SEC | Julie RubinsteinCOO, President | Sell Plan | 16,960431,950 held (−4%) | $13.79 | $234K | +92.1% | — |
| Apr 13SEC | Julie RubinsteinCOO, President | Sell Plan | 15,722424,512 held (−4%) | $12.95 | $204K | +104.6% | — |
| Apr 13SEC | Julie RubinsteinCOO, President | Sell Plan | 3,338421,174 held (−1%) | $14.08 | $47K | +88.1% | — |
| Apr 13SEC | Julie RubinsteinCOO, President | Sell Plan | 2,100429,850 held (−0%) | $14.44 | $30K | +83.4% | — |
| Apr 13SEC | Julie RubinsteinCOO, President | Sell Plan | 400425,512 held (−0%) | $13.48 | $5K | +96.5% | — |
| Apr 10SEC | Francis LoChief People Officer | Sell Plan | 22,564271,154 held (−8%) | $15.07 | $340K | +75.8% | — |
| Apr 10SEC | Harlan S RobinsChief Scientific Officer | Sell Plan | 10,0001,512,058 held (−1%) | $14.85 | $148K | +78.4% | — |
| Apr 8SEC | Chad M RobinsCEO, Chair | Sell Plan | 83,3322,217,781 held (−4%) | $14.41 | $1.2M | +83.8% | — |
| Apr 8SEC | Chad M RobinsCEO, Chair | Sell Plan | 37,2632,180,518 held (−2%) | $15.19 | $566K | +74.4% | — |
| Apr 8SEC | Julie RubinsteinCOO, President | Sell Plan | 30,841434,288 held (−7%) | $14.83 | $457K | +78.6% | — |
| Apr 8SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060442,864 held (−4%) | $14.33 | $273K | +84.9% | — |
| Apr 8SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060438,526 held (−4%) | $13.56 | $258K | +95.4% | — |
| Apr 8SEC | Julie RubinsteinCOO, President | Sell Plan | 100434,188 held (−0%) | $15.48 | $2K | +71.1% | — |
| Apr 2SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060447,202 held (−4%) | $14.60 | $278K | +81.4% | — |
| Apr 2SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060451,540 held (−4%) | $14.45 | $275K | +83.3% | — |
| Mar 31SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060455,878 held (−4%) | $13.45 | $256K | +97.0% | — |
| Mar 31SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060460,216 held (−4%) | $12.63 | $241K | +109.7% | — |
| Mar 31SEC | Julie RubinsteinCOO, President | Sell Plan | 16,322464,554 held (−3%) | $13.48 | $220K | +96.5% | — |
| Mar 31SEC | Julie RubinsteinCOO, President | Sell Plan | 2,738480,876 held (−1%) | $12.49 | $34K | +112.1% | — |
| Mar 26SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060473,230 held (−4%) | $14.27 | $272K | +85.6% | — |
| Mar 26SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060468,892 held (−4%) | $14.12 | $269K | +87.6% | — |
| Mar 26SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060477,568 held (−4%) | $13.70 | $261K | +93.4% | — |
| Mar 23SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060481,906 held (−4%) | $13.83 | $264K | +91.5% | — |
| Mar 23SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060486,244 held (−4%) | $13.37 | $255K | +98.1% | — |
| Mar 23SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060490,582 held (−4%) | $13.18 | $251K | +101.0% | — |
| Mar 18SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060503,596 held (−4%) | $13.41 | $256K | +97.5% | — |
| Mar 18SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060499,258 held (−4%) | $13.40 | $255K | +97.7% | — |
| Mar 18SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060494,920 held (−4%) | $13.18 | $251K | +101.0% | — |
| Mar 13SEC | Harlan S RobinsChief Scientific Officer | Sell | 329,6001,522,058 held (−18%) | $13.17 | $4.3M | +101.1% | — |
| Mar 13SEC | Chad M RobinsCEO, Chair | Sell | 329,6002,301,113 held (−13%) | $13.17 | $4.3M | +101.1% | — |
| Mar 13SEC | Harlan S RobinsChief Scientific Officer | Sell | 140,6661,851,658 held (−7%) | $13.17 | $1.9M | +101.1% | — |
| Mar 13SEC | Chad M RobinsCEO, Chair | Sell | 140,5672,630,713 held (−5%) | $13.17 | $1.9M | +101.1% | — |
| Mar 13SEC | Julie RubinsteinCOO, President | Sell Plan | 122,523520,948 held (−19%) | $13.17 | $1.6M | +101.1% | — |
| Mar 13SEC | Sharon BenzenoChief Commercial Ofc Imm Med | Sell | 63,103272,751 held (−19%) | $13.17 | $831K | +101.1% | — |
| Mar 13SEC | Susan BobulskyChief Commercial Officer, Mrd | Sell | 41,338427,775 held (−9%) | $13.17 | $544K | +101.1% | — |
| Mar 13SEC | Francis LoChief People Officer | Sell Plan | 30,593291,374 held (−10%) | $14.08 | $431K | +88.1% | — |
| Mar 13SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060516,610 held (−4%) | $14.08 | $268K | +88.1% | — |
| Mar 13SEC | Julie RubinsteinCOO, President | Sell Plan | 19,060507,934 held (−4%) | $12.96 | $247K | +104.4% | — |
| Mar 13SEC | Kyle PiskelCFO | Sell | 18,672259,840 held (−7%) | $13.17 | $246K | +101.1% | — |
| Mar 13SEC | Michelle Renee GriffinDirector | Sell | 15,39415,625 held (−50%) | $13.91 | $214K | +90.4% | — |
| Mar 13SEC | Julie RubinsteinCOO, President | Sell Plan | 13,660517,672 held (−3%) | $12.63 | $173K | +109.7% | — |
| Mar 13SEC | Julie RubinsteinCOO, President | Sell Plan | 5,400512,272 held (−1%) | $13.43 | $73K | +97.2% | — |
| Mar 10SEC | Julie RubinsteinCOO, President | Sell Plan | 30,941652,147 held (−5%) | $15.14 | $468K | +75.0% | — |
| Mar 10SEC | Julie RubinsteinCOO, President | Sell Plan | 30,941647,809 held (−5%) | $14.79 | $458K | +79.1% | — |
| Mar 10SEC | Julie RubinsteinCOO, President | Sell Plan | 19,460643,471 held (−3%) | $14.68 | $286K | +80.4% | — |
| Mar 9SEC | Francis LoChief People Officer | Sell | 38,074321,967 held (−11%) | $15.09 | $575K | +75.5% | — |
| Mar 5SEC | Michelle Renee GriffinDirector | Sell Plan | 48,04415,394 held (−76%) | $15.30 | $735K | +73.1% | — |
| Mar 5SEC | Julie RubinsteinCOO, President | Sell Plan | 30,941579,573 held (−5%) | $16.60 | $514K | +59.6% | — |
| Mar 5SEC | Julie RubinsteinCOO, President | Sell Plan | 30,941575,235 held (−5%) | $16.00 | $495K | +65.6% | — |
| Mar 5SEC | Julie RubinsteinCOO, President | Sell Plan | 24,423590,429 held (−4%) | $15.49 | $378K | +71.0% | — |
| Mar 5SEC | Julie RubinsteinCOO, President | Sell Plan | 6,518583,911 held (−1%) | $16.33 | $106K | +62.2% | — |
| Mar 4SEC | Harlan S RobinsChief Scientific Officer | Sell Plan | 14,2331,155,291 held (−1%) | $16.52 | $235K | +60.4% | — |
| Mar 4SEC | Harlan S RobinsChief Scientific Officer | Sell Plan | 10,0001,169,524 held (−1%) | $15.72 | $157K | +68.5% | — |
| Mar 3SEC | Chad M RobinsCEO, Chair | Sell Plan | 289,0241,987,330 held (−13%) | $15.82 | $4.6M | +67.4% | — |
| Mar 3SEC | Chad M RobinsCEO, Chair | Sell Plan | 182,8912,276,354 held (−7%) | $15.99 | $2.9M | +65.7% | — |
| Mar 3SEC | Chad M RobinsCEO, Chair | Sell Plan | 50,7031,936,627 held (−3%) | $15.49 | $785K | +71.0% | — |
| Mar 3SEC | Chad M RobinsCEO, Chair | Sell Plan | 2,3801,934,247 held (−0%) | $16.15 | $38K | +64.0% | — |
| Feb 6SEC | Kyle PiskelCFO | Sell Plan | 2,145216,637 held (−1%) | $18.46 | $40K | +43.5% | — |
| Feb 4SEC | Chad M RobinsCEO, Chair | Sell Plan | 124,9982,459,245 held (−5%) | $18.44 | $2.3M | +43.7% | — |
| Feb 4SEC | Harlan S RobinsChief Scientific Officer | Sell Plan | 34,6681,187,644 held (−3%) | $18.60 | $645K | +42.4% | — |
| Feb 4SEC | Harlan S RobinsChief Scientific Officer | Sell Plan | 8,1201,179,524 held (−1%) | $19.00 | $154K | +39.4% | — |
| Jan 14SEC | Francis LoChief People Officer | Sell Plan | 79,590315,978 held (−20%) | $17.73 | $1.4M | +49.4% | — |
| Jan 14SEC | Kyle PiskelCFO | Sell Plan | 4,290216,637 held (−2%) | $18.00 | $77K | +47.2% | — |
| Jan 8SEC | Harlan S RobinsChief Scientific Officer | Sell Plan | 10,0001,222,312 held (−1%) | $16.44 | $164K | +61.1% | — |
| Jan 7SEC | Chad M RobinsCEO, Chair | Sell Plan | 124,9982,584,243 held (−5%) | $15.59 | $1.9M | +69.9% | — |
| Jan 7SEC | Francis LoChief People Officer | Sell Plan | 4,394315,978 held (−1%) | $17.50 | $77K | +51.4% | — |
| Jan 6SEC | Francis LoChief People Officer | Sell Plan | 3,125315,978 held (−1%) | $16.08 | $50K | +64.7% | — |
| Dec 29SEC | Francis LoChief People Officer | Sell Plan | 4,394315,978 held (−1%) | $17.50 | $77K | +51.4% | — |
| Dec 17SEC | Francis LoChief People Officer | Sell Plan | 113,890315,978 held (−26%) | $15.57 | $1.8M | +70.1% | — |
| Dec 12SEC | Robert HershbergDirector | Sell | 22,96846,722 held (−33%) | $16.00 | $367K | +65.6% | — |
| Dec 8SEC | Sharon BenzenoChief Commercial Ofc Imm Med | Sell Plan | 12,604296,791 held (−4%) | $16.85 | $212K | +57.2% | — |
| Dec 5SEC | Harlan S RobinsChief Scientific Officer | Sell Plan | 27,2121,242,312 held (−2%) | $18.61 | $506K | +42.3% | — |
| Dec 5SEC | Harlan S RobinsChief Scientific Officer | Sell Plan | 10,0001,232,312 held (−1%) | $16.61 | $166K | +59.5% | — |
| Dec 2SEC | Kyle PiskelCFO | Sell Plan | 162,820216,637 held (−43%) | $19.50 | $3.2M | +35.8% | — |
| Dec 1SEC | Chad M RobinsCEO, Chair | Sell Plan | 124,9982,709,241 held (−4%) | $18.94 | $2.4M | +39.9% | — |
| Dec 1SEC | Chad M RobinsCEO, Chair | Sell Plan | 35,7362,834,239 held (−1%) | $19.68 | $703K | +34.6% | — |
| Nov 24SEC | Sharon BenzenoChief Commercial Ofc Imm Med | Sell Plan | 308,477296,791 held (−51%) | $16.91 | $5.2M | +56.7% | — |
| Nov 24SEC | Sharon BenzenoChief Commercial Ofc Imm Med | Sell Plan | 297,925296,791 held (−50%) | $16.54 | $4.9M | +60.2% | — |
| Nov 18SEC | Kyle PiskelCFO | Sell | 238269,343 held (−0%) | $14.05 | $3K | +88.5% | — |
| Nov 12SEC | Chad M RobinsCEO, Chair | Sell Plan | 86,1612,873,088 held (−3%) | $14.73 | $1.3M | +79.8% | — |
| Nov 12SEC | Harlan S RobinsChief Scientific Officer | Sell Plan | 10,0001,269,524 held (−1%) | $14.82 | $148K | +78.7% | — |
| Nov 12SEC | Chad M RobinsCEO, Chair | Sell Plan | 1,8672,869,975 held (−0%) | $15.00 | $28K | +76.6% | — |
| Nov 12SEC | Chad M RobinsCEO, Chair | Sell Plan | 1,2372,871,851 held (−0%) | $14.57 | $18K | +81.8% | — |
Insiders at Adaptive Biotechnologies Corp
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Chad M RobinsCEO, Chair | — | $39.8M | Aug 19, 2026 | — |
| Harlan S RobinsChief Scientific Officer | — | $29.6M | Jul 23, 2026 | — |
| Julie RubinsteinCOO, President | — | $15.3M | Oct 8, 2026 | — |
| Sharon BenzenoChief Commercial Ofc Imm Med | — | $14.7M | Jun 30, 2026 | — |
| Francis LoChief People Officer | — | $14.0M | Oct 5, 2026 | — |
| Kyle PiskelCFO | — | $3.6M | May 20, 2026 | — |
| Peter M NeupertDirector | — | $3.1M | Aug 19, 2026 | — |
| Michelle Renee GriffinDirector | — | $2.0M | Jun 29, 2026 | — |
| Susan BobulskyChief Commercial Officer, Mrd | — | $1.4M | Oct 8, 2026 | — |
| Robert HershbergDirector | — | $1.1M | Aug 20, 2026 | — |
| Katey Einterz OwenDirector | — | $250K | Aug 28, 2026 | — |
ADPT stock: common questions
Are Adaptive Biotechnologies Corp insiders buying ADPT stock?
In the past 12 months, 0 insiders reported open-market purchases of ADPT worth $0.
Are Adaptive Biotechnologies Corp insiders selling ADPT stock?
11 insiders reported sales worth $125M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ADPT's 52-week range?
Over the past year ADPT has traded between $12.41 and $29.84. It last closed at $26.49 on Oct 9, 2026.